Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $718000.0.

  • Verrica Pharmaceuticals' Share-based Compensation fell 6593.93% to $718000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 6006.13%. This contributed to the annual value of $7.2 million for FY2024, which is 5016.69% down from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' Share-based Compensation stood at $718000.0, which was down 6593.93% from $888000.0 recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Share-based Compensation ranged from a high of $9.7 million in Q3 2023 and a low of $718000.0 during Q3 2025
  • Moreover, its 5-year median value for Share-based Compensation was $1.4 million (2021), whereas its average is $1.9 million.
  • Per our database at Business Quant, Verrica Pharmaceuticals' Share-based Compensation skyrocketed by 58386.41% in 2023 and then crashed by 7818.48% in 2024.
  • Over the past 5 years, Verrica Pharmaceuticals' Share-based Compensation (Quarter) stood at $1.3 million in 2021, then dropped by 11.36% to $1.2 million in 2022, then skyrocketed by 77.2% to $2.1 million in 2023, then crashed by 63.57% to $756000.0 in 2024, then fell by 5.03% to $718000.0 in 2025.
  • Its Share-based Compensation stands at $718000.0 for Q3 2025, versus $888000.0 for Q2 2025 and $1.0 million for Q1 2025.